Cytokine changes during interferon-beta therapy in multiple sclerosis

Correlations with interferon dose and MRI response

Jerome J. Graber, David Ford, Min Zhan, Gordon Francis, Hillel Panitch, Suhayl Dhib-Jalbut

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-γ) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-β-1a 30 μg intramuscularly (IM) (n = 8) or three-times-weekly (tiw) IFN-β-1a 44 μg subcutaneously (SC) (n = 7). Overall, IFN-β treatment increased cellular IL-10 (p < 0.01) levels and the ratios of cellular IL-10/IL-12p40 (p < 0.01) and IL-10/IL-12p70 (p < 0.02) while cellular IFN-γ levels were reduced (p < 0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p < 0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p = 0.031) and a decrease in cellular IL-12p70 (p < 0.02). A decrease in cellular IFN-γ was observed in responders (p = 0.013). This is the first study that compares cytokine changes between the two IFN-β regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.

Original languageEnglish (US)
Pages (from-to)168-174
Number of pages7
JournalJournal of Neuroimmunology
Volume185
Issue number1-2
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Interleukin-12 Subunit p40
Interferon-beta
Interferons
Multiple Sclerosis
Cytokines
Therapeutics
Serum
Relapsing-Remitting Multiple Sclerosis

Keywords

  • Biomarker
  • Interferon-beta
  • Interferon-gamma
  • Interleukin-10
  • Interleukin-12
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Cytokine changes during interferon-beta therapy in multiple sclerosis : Correlations with interferon dose and MRI response. / Graber, Jerome J.; Ford, David; Zhan, Min; Francis, Gordon; Panitch, Hillel; Dhib-Jalbut, Suhayl.

In: Journal of Neuroimmunology, Vol. 185, No. 1-2, 04.2007, p. 168-174.

Research output: Contribution to journalArticle

Graber, Jerome J. ; Ford, David ; Zhan, Min ; Francis, Gordon ; Panitch, Hillel ; Dhib-Jalbut, Suhayl. / Cytokine changes during interferon-beta therapy in multiple sclerosis : Correlations with interferon dose and MRI response. In: Journal of Neuroimmunology. 2007 ; Vol. 185, No. 1-2. pp. 168-174.
@article{c0059fa6199b49698d8f06c9394ad037,
title = "Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response",
abstract = "We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-γ) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-β-1a 30 μg intramuscularly (IM) (n = 8) or three-times-weekly (tiw) IFN-β-1a 44 μg subcutaneously (SC) (n = 7). Overall, IFN-β treatment increased cellular IL-10 (p < 0.01) levels and the ratios of cellular IL-10/IL-12p40 (p < 0.01) and IL-10/IL-12p70 (p < 0.02) while cellular IFN-γ levels were reduced (p < 0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p < 0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p = 0.031) and a decrease in cellular IL-12p70 (p < 0.02). A decrease in cellular IFN-γ was observed in responders (p = 0.013). This is the first study that compares cytokine changes between the two IFN-β regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.",
keywords = "Biomarker, Interferon-beta, Interferon-gamma, Interleukin-10, Interleukin-12, Multiple sclerosis",
author = "Graber, {Jerome J.} and David Ford and Min Zhan and Gordon Francis and Hillel Panitch and Suhayl Dhib-Jalbut",
year = "2007",
month = "4",
doi = "10.1016/j.jneuroim.2007.01.011",
language = "English (US)",
volume = "185",
pages = "168--174",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Cytokine changes during interferon-beta therapy in multiple sclerosis

T2 - Correlations with interferon dose and MRI response

AU - Graber, Jerome J.

AU - Ford, David

AU - Zhan, Min

AU - Francis, Gordon

AU - Panitch, Hillel

AU - Dhib-Jalbut, Suhayl

PY - 2007/4

Y1 - 2007/4

N2 - We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-γ) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-β-1a 30 μg intramuscularly (IM) (n = 8) or three-times-weekly (tiw) IFN-β-1a 44 μg subcutaneously (SC) (n = 7). Overall, IFN-β treatment increased cellular IL-10 (p < 0.01) levels and the ratios of cellular IL-10/IL-12p40 (p < 0.01) and IL-10/IL-12p70 (p < 0.02) while cellular IFN-γ levels were reduced (p < 0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p < 0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p = 0.031) and a decrease in cellular IL-12p70 (p < 0.02). A decrease in cellular IFN-γ was observed in responders (p = 0.013). This is the first study that compares cytokine changes between the two IFN-β regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.

AB - We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-γ) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-β-1a 30 μg intramuscularly (IM) (n = 8) or three-times-weekly (tiw) IFN-β-1a 44 μg subcutaneously (SC) (n = 7). Overall, IFN-β treatment increased cellular IL-10 (p < 0.01) levels and the ratios of cellular IL-10/IL-12p40 (p < 0.01) and IL-10/IL-12p70 (p < 0.02) while cellular IFN-γ levels were reduced (p < 0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p < 0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p = 0.031) and a decrease in cellular IL-12p70 (p < 0.02). A decrease in cellular IFN-γ was observed in responders (p = 0.013). This is the first study that compares cytokine changes between the two IFN-β regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.

KW - Biomarker

KW - Interferon-beta

KW - Interferon-gamma

KW - Interleukin-10

KW - Interleukin-12

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=33947681258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947681258&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2007.01.011

DO - 10.1016/j.jneuroim.2007.01.011

M3 - Article

VL - 185

SP - 168

EP - 174

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -